Followers | 175 |
Posts | 10130 |
Boards Moderated | 3 |
Alias Born | 06/20/2022 |
Tuesday, December 05, 2023 8:45:06 AM
Recent ALLR News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 01:15:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:45:38 PM
- Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances • GlobeNewswire Inc. • 05/14/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/09/2024 03:21:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 01:47:15 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/08/2024 08:05:18 PM
- Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock • GlobeNewswire Inc. • 05/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 01:29:16 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2024 01:13:42 PM
- Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1 • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement • GlobeNewswire Inc. • 04/29/2024 11:00:00 AM
- Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) • GlobeNewswire Inc. • 04/17/2024 01:10:00 PM
- Allarity Therapeutics Announces 1-for-20 Reverse Stock Split • GlobeNewswire Inc. • 04/04/2024 01:15:00 PM
- Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1) • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 01:38:56 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 12:15:55 PM
- Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 03/08/2024 12:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/08/2024 02:45:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:05:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 02:21:14 PM
- Allarity Therapeutics to Present at Biomarkers 2024 • GlobeNewswire Inc. • 02/28/2024 11:00:00 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 02/23/2024 09:09:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 02:03:25 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • May 16, 2024 8:13 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM